## Adrian M Dubuc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11140088/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	1.2	83
2	Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 2022, 139, 2273-2284.	1.4	29
3	Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics, 2021, 37, 2461-2463.	4.1	21
4	Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes. Modern Pathology, 2021, 34, 1763-1779.	5.5	8
5	Twists and turns from "tumor in tumor―profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. Journal of Physical Education and Sports Management, 2021, 7, a006089.	1.2	0
6	From Banding to BAM Files. Surgical Pathology Clinics, 2020, 13, 343-347.	1.7	0
7	Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa155.	0.7	4
8	MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2020, 22, iii400-iii400.	1.2	0
9	<i>Sleeping Beauty</i> Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. Cancer Research, 2019, 79, 905-917.	0.9	33
10	Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). Genetics in Medicine, 2019, 21, 1903-1916.	2.4	39
11	<i>ZMYM2-FGFR1</i> fusion as secondary change in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 556-558.	1.3	Ο
12	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	35
13	TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?. Neuro-Oncology, 2018, 20, vi276-vi276.	1.2	0
14	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-Oncology, 2017, 19, now294.	1.2	54
15	From Prognostication to Personalized Medicine: Classification of Tumors of the Central Nervous System (CNS) Using Chromosomal Microarrays. Current Genetic Medicine Reports, 2017, 5, 117-124.	1.9	2
16	Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 2016, 1, e87062.	5.0	340
17	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpGâ€stimulated chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 978-983.	4.1	14
18	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurgery, 2016, 85, 96-105.	1.3	14

Adrian M Dubuc

#	Article	IF	CITATIONS
19	Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice. Journal of Neuro-Oncology, 2016, 126, 415-424.	2.9	15
20	Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. ELife, 2016, 5, .	6.0	21
21	Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathologica, 2015, 129, 449-457.	7.7	80
22	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nature Neuroscience, 2015, 18, 1236-1246.	14.8	74
23	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Research, 2015, 75, 134-146.	0.9	51
24	Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion. Acta Neuropathologica Communications, 2014, 2, 10.	5.2	29
25	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
26	<i>Bmi1</i> overexpression in the cerebellar granule cell lineage of mice affects cell proliferation and survival without initiating medulloblastoma formation. DMM Disease Models and Mechanisms, 2013, 6, 49-63.	2.4	15
27	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 2013, 125, 373-384.	7.7	169
28	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
29	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
30	Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma. Neurosurgery, 2013, 60, 57-63.	1.1	13
31	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes and Development, 2012, 26, 1780-1796.	5.9	68
32	Molecular subgroups of medulloblastoma. Expert Review of Neurotherapeutics, 2012, 12, 871-884.	2.8	142
33	The Epigenetics of Brain Tumors. Methods in Molecular Biology, 2012, 863, 139-153.	0.9	38
34	Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathologica, 2012, 123, 485-499.	7.7	28
35	The Genetics of Pediatric Brain Tumors. Current Neurology and Neuroscience Reports, 2010, 10, 215-223.	4.2	69
36	Calculating a cure for cancer: managing medulloblastoma MATH1-ematically. Expert Review of Neurotherapeutics, 2010, 10, 1489-1492.	2.8	7